Table 2 Chest radiological imaging quantification.

From: Efficacy and tolerability of bevacizumab in patients with severe Covid-19

 

n

Baseline

Day 3

p-value

Day 7

p-value

Chest CT quantification

      

 Patchy shadow, median [IQR], numbers

8

2.5 (0, 4.0)

–

–

1.5 (0, 3.5)

0.641

 Ground-glass opacity, median [IQR], numbers

8

3.5 (1.5, 7.0)

–

–

6.5 (3.5, 10.5)

0.094

 Total Lesion area, median [IQR], cm3

8

1055.8 (532.8, 1409.4)

–

–

680.7 (395.9, 926.2)

0.039

 Lesion ratio, median [IQR], %—right lung

8

19.2 (12.8, 33.6)

–

–

12.4 (9.7, 15.6)

0.023

 Lesion ratio, median [IQR], %—left lung

8

35.7 (25.0, 45.2)

–

–

17.7 (13.0, 31.8)

0.016

Chest X-ray semi-quantification

 Lesion ratio, median [IQR], %— right lung

12

48.5 (30.7, 71.8)

34.0 (23.4, 50.7)

0.024

26.7 (4.6, 36.4)

0.005

 Lesion ratio, median [IQR], %— left lung

12

47.6 (39.4, 72.8)

39.8 (30.8, 49.6)

0.077

28.1 (18.8, 55.2)

0.052

  1. Chest radiological imaging quantification results are based on available images. Chest CT images on baseline and day 7 post-bevacizumab treatment were from 6 Chinese patients and 2 Italian patients. Chest X-ray images on baseline, days 3 and 7 post-bevacizumab treatment were from 12 Italian patients. Patient nos. 15, 19, 21, 22, and 23 were unable to receive chest radiological examination on required time points, although they recovered well (shown in Fig. 3). Patient no. 26 was discharged on day 4. CT computed tomography, IQR interquartile range; Wilcoxon matched-pairs signed-rank test was used to calculate the p-values between day 3 and baseline, and day 7 and baseline. p < 0.05 for two-tailed hypothesis tests was considered statistically significant. Source data are provided as a Source Data file.
Back to article page